Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab for pediatric AQP4 antibody-positive NMOSD (Phase II/III)
2023-508534-33-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Primary endpoints: Change from baseline in annualized relapse rate and Time to First Adjudicated On-trial Relapse. Planned start Jun 2022; status: authorised.
02
Drugs
ravulizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2023-508534-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508534-33-00.